Premium
FK506 (tacrolimus) inhibits extravasation of lymphoid cells by abrogating VLA‐4/VCAM‐1 mediated transendothelial migration
Author(s) -
Tsuzuki Shinobu,
Toyama-Sorimachi Noriko,
Kitamura Fujiko,
Tobita Yoshimi,
Miyasaka Masayuki
Publication year - 1998
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(98)00703-0
Subject(s) - extravasation , leukocyte extravasation , calcineurin , in vitro , tacrolimus , infiltration (hvac) , in vivo , chemistry , microbiology and biotechnology , immunology , addressin , cancer research , inflammation , biology , transplantation , cell adhesion , cell , medicine , biochemistry , physics , thermodynamics , surgery
Extravasation is a critical process for the physiological lymphocyte traffic as well as the hematogenous spread of malignant hemopoietic cells. Here we report that abrogation of calcineurin activity leads to in vitro transendothelial migration and in vivo infiltration of human lymphoma Nalm‐6 cells, which are associated with the abrogation of the VLA‐4/VCAM‐1 mediated pathway. Rapamycin, which can antagonize FK506 but not CsA to inhibit calcineurin, abrogates FK‐506 mediated but not CsA mediated inhibition of in vitro transendothelial migration. FK506 may exert its potent immunosuppressive action partly by inhibiting VLA‐4/VCAM‐1 mediated transendothelial migration or insinuation of lymphoid cells to tissues.